Home ›
NPI 1871574822
NPI deactivated
1871574822
1871574822 was paid $2.93M by Medicaid between Jan 2018 and Sep 2023, across 52 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider info1871574822
33aNPI1871574822
33bProvider type—
28Total paid$2.93M
24GClaims56,533
24DCodes billed52
24AFirst – last monthJan 2018 – Sep 2023
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,440 | $234K | |
| 2019 | 6,851 | $325K | |
| 2020 | 5,298 | $275K | |
| 2021 | 8,779 | $499K | |
| 2022 | 15,018 | $930K | |
| 2023 | 9,147 | $663K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 7,891 | 7,074 | $1.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 4,412 | 3,676 | $592K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 3,365 | 2,612 | $377K |
| 71045 | Radiologic examination, chest; single view | 7.6% | 1,652 | 1,411 | $222K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 1,709 | 1,419 | $99K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 1,546 | 1,261 | $91K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 610 | 573 | $50K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 510 | 437 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 7,319 | 6,114 | $34K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 8,471 | 7,160 | $31K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.0% | 676 | 621 | $30K |
| 80053 | Comprehensive metabolic panel | <1% | 5,126 | 4,274 | $29K |
40 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 753 | $24K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 634 | $17K |
| 87503 | <1% | 610 | $15K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 229 | $15K |
| 84484 | <1% | 1,402 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,004 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 580 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 498 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 320 | $5K |
| 80050 | General health panel | <1% | 28 | $4K |
| 83605 | <1% | 705 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 112 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 49 | $4K |
| 83690 | <1% | 942 | $4K | |
| 80076 | <1% | 479 | $3K | |
| 87276 | <1% | 514 | $3K | |
| 87275 | <1% | 514 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 26 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 166 | $2K |
| 81003 | <1% | 1,177 | $2K | |
| 83880 | <1% | 80 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 175 | $1K |
| 81001 | <1% | 739 | $1K | |
| 81025 | <1% | 189 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 206 | $873.18 |
| 82150 | <1% | 244 | $851.73 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $748.44 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 344 | $655.16 |
| 83735 | <1% | 95 | $534.57 | |
| 84100 | <1% | 82 | $395.66 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 29 | $253.86 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14 | $201.74 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 40 | $154.09 |
| 80061 | Lipid panel | <1% | 12 | $107.12 |
| 82553 | <1% | 61 | $82.87 | |
| 82550 | <1% | 61 | $81.88 | |
| 85379 | <1% | 16 | $60.90 | |
| 87040 | <1% | 21 | $44.50 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 43 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.